Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma

Neuroendocrine prostate cancer (NEPC) may be rising in prevalence as patients with advanced prostate cancer potentially develop resistance to contemporary anti-androgen treatment through a neuroendocrine phenotype.